4-(2-丙炔基)苯甲腈 | 1260663-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-丙炔基)苯甲腈
• 英文名称: 4-(2-propynyl)benzonitrile
• 英文别名: 4-(Prop-2-YN-1-YL)benzonitrile；4-prop-2-ynylbenzonitrile
• CAS: 1260663-61-3
• 化学式: C₁₀H₇N
• 分子量: 141.172
• InChiKey: FBTKJZVYFGLMEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(2-丙炔基)苯甲腈 在 lithium aluminium tetrahydride 、 sodium azide 、 copper(ll) sulfate pentahydrate 、 sodium hydride 、 sodium carbonate 、 sodium hydroxide 、 维生素 C 作用下， 以 四氢呋喃 、 乙醚 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 7.0h， 生成 N-(tert-butoxycarbonyl)-N-methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors

  摘要：

  Different azides and alkynes have been coupled via Cu-catalyzed 1,3-dipolar Huisgen cycloaddition to afford a novel family of N-1- and C-5-substituted 1,2,3-triazole derivatives that feature the propargylamine group typical of irreversible MAO-B inhibitors at the C4-side chain of the triazole ring. All the synthesized compounds were evaluated against human MAO-A and MAO-B. Structure-activity relationships and molecular modeling were utilized to gain insight into the structural and chemical features that enhance the binding affinity and selectivity between the two enzyme isoforms. Several lead compounds, in terms of potency (submicromolar to low micromolar range), MAO-B selective recognition, and brain permeability, were identified. One of these leads (MAO-B IC50 of 3.54 mu M, selectivity MAO-A/MAO-B index of 27.7) was further subjected to reversibility and time-dependence inhibition studies, which disclosed a slow and irreversible inhibition of human MAO-B. Overall, the results support the suitability of the 4-triazolylalkyl propargylamine scaffold for exploring the design of multipotent anti-Alzheimer compounds endowed with irreversible MAO-B inhibitory activity. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.06.045
• 作为产物：
  描述：

  4-[3-(trimethylsilyl)-2-propynyl]benzonitrile 在 silver trifluoromethanesulfonate 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 7.0h， 以81%的产率得到4-(2-丙炔基)苯甲腈
  参考文献：
  名称：

  Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors

  摘要：

  Different azides and alkynes have been coupled via Cu-catalyzed 1,3-dipolar Huisgen cycloaddition to afford a novel family of N-1- and C-5-substituted 1,2,3-triazole derivatives that feature the propargylamine group typical of irreversible MAO-B inhibitors at the C4-side chain of the triazole ring. All the synthesized compounds were evaluated against human MAO-A and MAO-B. Structure-activity relationships and molecular modeling were utilized to gain insight into the structural and chemical features that enhance the binding affinity and selectivity between the two enzyme isoforms. Several lead compounds, in terms of potency (submicromolar to low micromolar range), MAO-B selective recognition, and brain permeability, were identified. One of these leads (MAO-B IC50 of 3.54 mu M, selectivity MAO-A/MAO-B index of 27.7) was further subjected to reversibility and time-dependence inhibition studies, which disclosed a slow and irreversible inhibition of human MAO-B. Overall, the results support the suitability of the 4-triazolylalkyl propargylamine scaffold for exploring the design of multipotent anti-Alzheimer compounds endowed with irreversible MAO-B inhibitory activity. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.06.045

文献信息

• [EN] HISTONE DEMENTHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014164708A1

  公开（公告）日：2014-10-09

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代吡咯吡啶衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物对组蛋白去甲基化酶的抑制具有用处。此外，所述化合物和组合物对癌症的治疗具有用处，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• Development of Highly Chemoselective Bulky Zincate Complex,<i>t</i>Bu₄ZnLi₂: Design, Structure, and Practical Applications in Small-/Macromolecular Synthesis
  作者：Taniyuki Furuyama、Mitsuhiro Yonehara、Sho Arimoto、Minoru Kobayashi、Yotaro Matsumoto、Masanobu Uchiyama

  DOI：10.1002/chem.200800536

  日期：2008.11.17

  We present full details of the unique reactivities of the newly developed dianion-type bulky zincate, dilithium tetra-tert-butylzincate (tBu(4)ZnLi(2)). With this reagent, halogen-zinc exchange reaction of variously functionalized haloaromatics and anionic polymerization of N-isopropylacrylamide (NIPAm)/styrene with excellent chemoselectivity were realized. Halogen-zinc exchange reaction followed by

  我们介绍了新开发的二价阴离子型大体积锌酸盐，四叔丁基锌酸二锂（tBu（4）ZnLi（2））的独特反应性的完整细节。用这种试剂，实现了具有多种化学官能度的各种官能化卤代芳烃的卤素-锌交换反应和N-异丙基丙烯酰胺（NIPAm）/苯乙烯的阴离子聚合。卤素-锌交换反应，然后用炔丙基溴进行亲电捕集，提供了一条通向官能化苯丙烯的便捷途径，特别是那些具有亲电官能团（如氰基，酰胺和卤素）的苯丙二烯。气相和液相结构的光谱和计算研究表明，该二价阴离子型锌酸盐通过其庞大的配体具有非凡的稳定性。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：QUANTICEL PHARMACEUTICALS, INC.

  公开号：US20160194315A1

  公开（公告）日：2016-07-07

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明涉及治疗癌症和肿瘤疾病的组合物和方法。本发明提供了取代吡咯吡啶衍生物化合物和含有该化合物的制药组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• Histone demethylase inhibitors
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US10174026B2

  公开（公告）日：2019-01-08

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本发明提供了取代的吡咯并吡啶衍生物化合物和包含所述化合物的药物组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物还可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• HISTONE DEMENTHYLASE INHIBITORS
  申请人：Celgene Quanticel Research, Inc.

  公开号：EP2968282B1

  公开（公告）日：2018-05-09